

Original Article

Trends in infective endocarditis hospitalisations at United States children's hospitals from 2003 to 2014: impact of the 2007 American Heart Association antibiotic prophylaxis guidelines

Katherine E. Bates,¹ Matthew Hall,² Samir S. Shah,³ Kevin D. Hill,⁴ Sara K. Pasquali¹

¹*Congenital Heart Center, C.S. Mott Children's Hospital, University of Michigan Medical School, Ann Arbor, Michigan;* ²*Children's Hospital Association, Overland Park, Kansas;* ³*Division of Hospital Medicine and Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio;* ⁴*Duke University Medical Center and the Duke Clinical Research Institute, Durham, North Carolina, United States of America*

Abstract *Objective:* National organisations in several countries have recently released more restrictive guidelines for infective endocarditis prophylaxis, including the American Heart Association 2007 guidelines. Initial studies demonstrated no change in infective endocarditis rates over time; however, a recent United Kingdom study suggested an increase; current paediatric trends are unknown. *Methods:* Children (<18 years) hospitalised with infective endocarditis at 29 centres participating in the Pediatric Health Information Systems Database from 2003 to 2014 were eligible for inclusion. Our primary analysis focussed on infective endocarditis most directly related to the change in guidelines and included community-acquired cases in those >5 years of age. Interrupted time series analysis was used to evaluate rates over time indexed to total hospitalisations. *Results:* A total of 841 cases were identified. The median age was 13 years (interquartile range 9–15 years). In the pre-guideline period, there was a slight increase in the rate of infective endocarditis by 0.13 cases/10,000 hospitalisations per semi-annual period. In the post-guideline period, the rate of infective endocarditis increased by 0.12 cases/10,000 hospitalisations per semi-annual period. There was no significant difference in the rate of change in the pre- versus post-guidelines period ($p = 0.895$). Secondary analyses in children >5 years of age with CHD and in children hospitalised with any type of infective endocarditis at any age revealed similar results. *Conclusions:* We found no significant change in infective endocarditis hospitalisation rates associated with revised prophylaxis guidelines over 11 years across 29 United States children's hospitals.

Keywords: Endocarditis; antibiotic prophylaxis; paediatrics

Received: 19 April 2016; Accepted: 12 June 2016; First published online: 15 July 2016

SEVERAL COUNTRIES HAVE RECENTLY REVISED guidelines for infective endocarditis prophylaxis with a general trend towards limiting or discontinuing antibiotics completely, reflecting concerns about the risk–benefit ratio of prophylaxis.^{1–3} In 2007, the American Heart Association released an updated guideline that recommended restricting antibiotic prophylaxis before dental work to only

patients at the greatest risk of adverse outcomes from infective endocarditis.⁴

Studies across multiple countries have reported mixed results regarding rates of infective endocarditis following release of these more restrictive guidelines. Early reports from the United Kingdom, France, and the United States of America found no increase in hospitalisations following the release of guidelines recommending more restrictive prophylaxis.^{5–8} Although these studies focussed primarily or exclusively on adult hospitalisations, Pasquali et al⁹ also reported no increase in infective endocarditis hospitalisations across United States children's hospitals in the

Correspondence to: K. E. Bates, MD, Congenital Heart Center, C.S. Mott Children's Hospital, University of Michigan Medical School, 1540 E. Hospital Drive, Ann Arbor, MI 48109, United States of America. Tel: 734 936 2537; Fax: 734 936 4628; E-mail: kebates@med.umich.edu

first 3 years following publication of the American Heart Association guidelines. In contrast, more recent studies over longer time periods in both the United Kingdom and the United States of America have suggested an increase in infective endocarditis rates;^{10,11} however, as these studies primarily focussed on adults, contemporary infective endocarditis trends in children remain unclear. The paediatric population is of particular interest as it includes children with CHD, a population in which the American Heart Association guidelines significantly restricted prophylaxis, and thus may be the most likely to be impacted by this change in guidelines. Therefore, the purpose of the present study was to examine recent trends in paediatric infective endocarditis hospitalisations in the United States over time, before and after the 2007 American Heart Association antibiotic prophylaxis guidelines.

Methods

Data source

The Pediatric Health Information System Database was utilised for this multicentre, retrospective study. This database is a large administrative data set containing inpatient data from over 40 children's hospitals in the United States of America affiliated with the Children's Hospital Association (Overland Park, KS). The database currently contains information from nearly six million inpatient discharges and has been used extensively in paediatric outcomes research.^{12–14} Participating hospitals provide discharge data including patient demographics, *International Classification of Diseases (ICD)* diagnosis and procedure codes, as well as billing data such as medications, imaging studies, laboratory tests, and supplies charged to each patient. Data quality and reliability are promoted through systematic monitoring including bimonthly coding consensus meetings, coding consistency reviews, and quarterly data reports. This study, using a de-identified data set, was not considered human subjects research by the University of Michigan Institutional Review Board.

Study population and data collection

Centres that submitted complete inpatient data to the Pediatric Health Information System, including medication data, from 2003 to 2014 ($n = 29$) were included. This time period was chosen to include the period before and after the 2007 American Heart Association antibiotic prophylaxis guidelines were published and to maximise the number of eligible hospitals. From these centres, we identified children ≤ 18 years of age hospitalised with infective endocarditis – defined as having an ICD-9 diagnosis code

for “acute and subacute bacterial endocarditis” (421.0). Only the first (index) hospitalisation for infective endocarditis was analysed, which was enabled by using the patient identifiers available within the database, allowing exclusion of subsequent admissions at the same hospital. Our primary analysis focussed on infective endocarditis cases most directly related to the American Heart Association guideline change, which are community-acquired cases related to oral streptococcal species in those children likely to be receiving dental care. These cases were identified in the database as children >5 years of age, having an infective endocarditis diagnosis code as defined above, and a code for administration of any intravenous antibiotic covering an oral streptococcal species within 7 days of admission. Anti-streptococcal antibiotics were defined as any of the following on the basis of the American Heart Association guidelines for the treatment of infective endocarditis:¹⁵ monotherapy with vancomycin, penicillin, or ceftriaxone; combination therapy with vancomycin and gentamicin; or ceftriaxone or penicillin plus gentamicin.

In addition, two secondary cohorts were evaluated. The first was the subgroup with CHD, which was identified using the same criteria as specified in the preceding section, but then further limited to those patients with any diagnostic or procedural code related to CHD.¹⁶ The other secondary cohort was a broader cohort including children of any age hospitalised with community-acquired infective endocarditis. Inclusion to this cohort required a diagnosis code for infective endocarditis, as specified in the preceding section, and administration of any intravenous antibiotic within 7 days of hospital admission, with no restrictions on age or type of antibiotics.

In addition to data regarding infective endocarditis, patient demographic information and mortality data were also recorded.

Analysis

Standard summary statistics were used to describe study variables, and were compared using χ^2 or Wilcoxon's ranked-sum tests as appropriate. Infective endocarditis rates were indexed to the total number of hospitalisations, because raw rates could simply reflect changes in hospital catchment area or referral patterns. Indexed infective endocarditis rates and 95% confidence intervals were analysed semi-annually. The mean rates in the pre- and post-guideline periods were calculated and compared using the Wilcoxon's ranked-sum test. Segmented regression analysis of interrupted time series was then used to model indexed semi-annual infective endocarditis rates over time to assess whether the guideline had an effect at the time of introduction or whether the guideline

altered the trajectory of the infective endocarditis rate from the pre-guideline period trend. All analyses were performed using SAS v.9.4 (SAS Institute, Cary, North Carolina, United States of America), and $p < 0.05$ was considered to be statistically significant.

Results

Study population characteristics

In our primary cohort, 841 infective endocarditis cases were identified during the study period across the 29 hospitals. Patient demographics and outcomes are summarised in Table 1. The median age was 13 years, 57% were males, and approximately one-third were coded as having CHD. The in-hospital mortality rate was 4%.

Infective endocarditis rates in the pre- and post-guideline period

The indexed rates of infective endocarditis per semi-annual period are shown in Figure 1. In the pre-guideline period, the mean infective endocarditis rate in the primary cohort was 4.6/10,000 hospitalisations per semi-annual period. In the post-guideline period, the mean rate was also 4.6/10,000 hospitalisations per semi-annual period ($p = 0.194$).

Interrupted time series analysis

In the pre-guideline period, the rate of infective endocarditis increased by 0.13 cases/10,000 hospitalisations per semi-annual period (Fig 2). In the post-guideline period, the rate of infective endocarditis increased by 0.12 cases/10,000 hospitalisations per semi-annual period. Thus, overall, there was a slight increase in infective endocarditis over time, but no significant difference in the rate of change in the pre- versus post-guidelines period ($p = 0.895$).

Secondary analyses

In the CHD subgroup, we identified 288 infective endocarditis cases. Similar to the main findings, there was no significant difference in the infective endocarditis rate in the pre- versus post-guideline period in this cohort: we found an increase of

Table 1. Study population characteristics of the primary cohort.

	n = 841
Age (median [interquartile range] (years))	13 [9, 15]
Gender (male)	476 (56.6%)
CHD	288 (34.2%)
In-hospital mortality	30 (3.6%)

0.02 cases/10,000 hospitalisations per semi-annual period versus 0.06 cases/10,000 hospitalisations per semi-annual period ($p = 0.539$).




Figure 1.

Infective endocarditis rates over time. Raw rate of infective endocarditis in the primary study cohort per 10,000 hospitalisations per semi-annual period with 95% confidence intervals indicated by the shaded area. The vertical line in 2007 indicates release of the 2007 American Heart Association guidelines. There was no significant difference in the mean rate in the pre-guideline period compared with the post-guideline period – 4.6 cases/10,000 hospitalisations per semi-annual period versus 4.6 cases/10,000 hospitalisations per semi-annual period ($p = 0.194$).




Figure 2.

Interrupted time series analysis. The interrupted time series analysis in the primary study cohort is displayed. The vertical line indicates the 2007 American Heart Association guideline release, and the solid line indicates the observed rate of endocarditis. In the interrupted time series analysis, the pre-guideline trajectory is indicated by the dashed line, and the post-guideline trajectory by the dash-dot line. For comparison, the dotted line indicates the expected trajectory if the pre-guideline rates were extended over time. In the pre-guideline period, the rate of endocarditis increased by 0.13 cases/10,000 hospitalisations per semi-annual period versus 0.12 cases/10,000 hospitalisations per semi-annual period in the post-guideline period ($p = 0.895$).

In the broad cohort of all children hospitalised with infective endocarditis, there were 1722 cases identified. Again, similar to the main findings, there was no significant difference in the infective endocarditis rate in the pre- versus post-guideline period in this cohort: we found an increase of 0.06 cases/10,000 hospitalisations per semi-annual period versus 0.02 cases/10,000 hospitalisations per semi-annual period ($p = 0.579$).

Discussion

We analysed infective endocarditis rates over 11 years across 29 United States children's hospitals. Our results suggest that in general infective endocarditis rates have increased slightly over time; however, we did not detect any change in the rate of increase before versus after the revised 2007 American Heart Association antibiotic prophylaxis guidelines.

The increase in infective endocarditis admissions over time demonstrated in our study is consistent with the results of multiple previous studies across the United States of America and other countries.^{8,10,11} Pant et al¹¹ cite the increased survival of CHD patients as well as the increased use of prosthetic devices and procedures resulting in transient bacteraemia as possible reasons for the overall increase in infective endocarditis incidence in United States adults. Other possible reasons for this may include more sensitive diagnostic techniques¹¹ or improved coding in administrative data sets. Another possible reason specific to this study may be an increasing tendency for these patients to be cared for in tertiary children's hospitals rather than community settings.

Although multiple earlier studies following the release of more restrictive prophylaxis guidelines have suggested no change in the increase of infective endocarditis rates, two more recent studies have suggested increases in infective endocarditis following guideline changes. Pant et al¹¹ recently reported significant increase in streptococcal infective endocarditis hospitalisation rates in United States adults without any increase in the overall infective endocarditis hospitalisation rate after the 2007 American Heart Association guidelines were released. Dayer et al also recently reported an increase in infective endocarditis in the United Kingdom following the change in guidelines in 2008. The ability to track outpatient prescriptions, which declined sharply after the change in guidelines, as well as infective endocarditis hospitalisations in the United Kingdom's National Health System is a particular strength of the Dayer study.¹⁰ In contrast to these reports, our study found no difference in infective endocarditis rates over time in a paediatric cohort before and after the release of the 2007 American Heart Association

guidelines. These differences between studies may be due to the more restrictive recommendations in the United Kingdom guidelines, which recommended the complete cessation of infective endocarditis prophylaxis for essentially all populations.¹ In contrast, the American Heart Association guidelines recommend continuing prophylaxis for specific cardiac conditions with the highest risk of adverse outcome from infective endocarditis. Differences in study population or methodology could also account for differences in findings. Dayer et al's study included data from the entire United Kingdom national health system in contrast to our study population of patients admitted to United States children's hospitals. Another explanation for this difference could be lower rates of compliance with the guidelines among paediatric care providers in the United States of America.^{17,18} Unfortunately, in contrast to the data available in the United Kingdom, comprehensive prescribing data in the United States of America are not as easily accessible.

Novel approaches utilised in our study include the use of inpatient antibiotic data to increase the specificity in identifying cases of infective endocarditis related to oral streptococcal species and our focus on selecting community-acquired cases of infective endocarditis in children most likely to be receiving dental care. These criteria are important as, although there may be changes in hospital-acquired cases or non-streptococcal cases when evaluating the overall cohort of patients with infective endocarditis, these cases are less likely to be related to the change in guidelines. The inpatient antibiotic data are particularly useful as previous studies have found that diagnostic codes for specific microorganisms are missing in many cases.^{9,10} Thus, our study serves as an example of the potential strengths of taking advantage of the full array of information available in data sets such as the Pediatric Health Information System Database in addition to the diagnosis and procedural codes. In addition, as a check to ensure that our selection criteria did not inadvertently exclude patients of interest, we also evaluated the overall cohort of patients with infective endocarditis and found no change in this group in the pre- and post-guidelines period.

Limitations

The general limitations associated with the use of administrative data apply to this study, including lack of clinical detail. Specifically for this study, lack of validation of infective endocarditis cases is a limitation; however, our combined use of discharge diagnosis codes and antibiotic administration minimises the likelihood that children without infective

endocarditis were included. In addition, our ability to identify patients across hospital admissions ensures that repeat encounters for infective endocarditis for the same patient at a given hospital were not inadvertently included. In addition, although our study included a large sample of children's hospitals, the generalisability of these findings to other children's hospitals or other populations is unclear. It is also possible that our study may be underpowered to detect differences over time; however, our point estimates do not suggest that there are clinically important differences present that we were not able to demonstrate statistically. Finally, as we do not know the size of the population at risk for infective endocarditis in this data set, the incidence cannot be calculated using these data.

Conclusions

This multicentre analysis of infective endocarditis hospitalisations across 29 United States children's hospitals found no significant change in hospitalisation rates following release of the revised 2007 American Heart Association infective endocarditis prophylaxis guidelines. Given the rarity of infective endocarditis, further study over time is necessary. In addition, the general increase in the rate of infective endocarditis over time found in our study and others suggests that a better understanding of the current epidemiology of infective endocarditis and further study of the underlying risk factors are needed in order to reverse these trends.

Acknowledgements

None.

Financial Support

K.D.H. receives salary support for research from the National Center for Advancing Translational Sciences of the NIH (KL2TR001115-02), from the Gilead Sciences Cardiovascular scholars program, and from industry for paediatric drug development (www.dcri.duke.edu/research/coi.jsp). S.K.P. receives support from the Janette Ferrantino Professorship.

Conflicts of Interest

None.

References

1. National Institute for Health and Care Excellence. Prophylaxis against infective endocarditis. Retrieved January 4, 2016, from <https://www.nice.org.uk/guidance/cg64>.
2. Habib G, Hoen B, Tornos P, et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009):

- the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). *Eur Heart J* 2009; 30: 2369–2413.
3. Danchin N. Prophylaxis of infective endocarditis: French recommendations 2002. *Heart* 2005; 91: 715–718.
4. Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. *Circulation* 2007; 116: 1736–1754.
5. Duval X, Delahaye F, Alla F, et al. Temporal trends in infective endocarditis in the context of prophylaxis guideline modifications. *J Am Coll Cardiol* 2012; 59: 1968–1976.
6. DeSimone DC, Tleyjeh IM, Correa de Sa DD, et al. Incidence of infective endocarditis caused by viridans group streptococci before and after publication of the 2007 American Heart Association's endocarditis prevention guidelines. *Circulation* 2012; 126: 60–64.
7. Bikdeli B, Wang Y, Kim N, Desai MM. Trends in hospitalization rates and outcomes of endocarditis among Medicare beneficiaries. *J Am Coll Cardiol* 2013; 62: 2217–2226.
8. Thornhill MH, Dayer MJ, Forde JM, et al. Impact of the NICE guideline recommending cessation of antibiotic prophylaxis for prevention of infective endocarditis: before and after study. *BMJ* 2011; 342: d2392.
9. Pasquali SK, He X, Mohamad Z, et al. Trends in endocarditis hospitalizations at US children's hospitals: impact of the 2007 American Heart Association antibiotic prophylaxis guidelines. *Am Heart J* 2012; 163: 894–899.
10. Dayer MJ, Jones S, Prendergast B, Baddour LM, Lockhart PB, Thornhill MH. Incidence of infective endocarditis in England, 2000–13: a secular trend, interrupted time-series analysis. *Lancet* 2015; 385: 1219–1228.
11. Pant S, Patel NJ, Deshmukh A, et al. Trends in infective endocarditis incidence, microbiology, and valve replacement in the United States from 2000 to 2011. *J Am Coll Cardiol* 2015; 65: 2070–2076.
12. Morse RB, Hall M, Fieldston ES, et al. Children's hospitals with shorter lengths of stay do not have higher readmission rates. *J Pediatr* 2013; 163: 1034–1038.
13. Berry JG, Hall DE, Kuo DZ, et al. Hospital utilization and characteristics of patients experiencing recurrent readmissions within children's hospitals. *JAMA* 2011; 305: 682–690.
14. Pasquali SK, Li JS, He X, et al. Perioperative methylprednisolone and outcome in neonates undergoing heart surgery. *Pediatrics* 2012; 129: e385–e391.
15. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. *Circulation* 2005; 111: e394–e434.
16. Jenkins KJ, Gauvreau K, Newburger JW, Spray TL, Moller JH, Iezzoni LI. Consensus-based method for risk adjustment for surgery for congenital heart disease. *J Thorac Cardiovasc Surg* 2002; 123: 110–118.
17. Pharis CS, Conway J, Warren AE, Bullock A, Mackie AS. The impact of 2007 infective endocarditis prophylaxis guidelines on the practice of congenital heart disease specialists. *Am Heart J* 2011; 161: 123–129.
18. Naik RJ, Patel NR, Wang M, Shah NC. Infective endocarditis prophylaxis: current practice trend among paediatric cardiologists: are we following the 2007 guidelines? *Cardiol Young* 2015; 93: 1–7.